Sutent (Sunitinib Malate) Patent Expiration, LOE Window & CMS Spending

Sutent (Sunitinib Malate) by Cp International Cv: Off-Patent Genericized (AB Competition), 8 AB generics, $9.2M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCp International Cv
FDA Application & PathwayN021938 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$9.2M
2024 Medicare Part D Spend$4.6M
2024 Medicaid Spend$4.6M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 16.3% 2-yr change)